Advanced

Interleukin-17 as a drug target in human disease

Ivanov, Stefan LU and Linden, Anders (2009) In Trends in Pharmacological Sciences 30(2). p.95-103
Abstract
Interleukin (IL)-17 (now synonymous with IL-17A) is an archetype molecule for an entire family of IL-17 cytokines. Currently believed to be produced mainly by a specific subset of CD4 cells, named Th-17 cells, IL-17 is functionally located at the interface of innate and acquired immunity. Specifically, it induces the release of chemokines and growth factors from mesenchymal cells and is now emerging as an important local orchestrator of neutrophil accumulation in several mammalian organs. Furthermore, there is growing evidence that targeting IL-17 signaling might prove useful in a variety of diseases including asthma, Crohn's disease, multiple sclerosis, psoriatric disease and rheumatoid arthritis. Here, we summarize the key aspects of the... (More)
Interleukin (IL)-17 (now synonymous with IL-17A) is an archetype molecule for an entire family of IL-17 cytokines. Currently believed to be produced mainly by a specific subset of CD4 cells, named Th-17 cells, IL-17 is functionally located at the interface of innate and acquired immunity. Specifically, it induces the release of chemokines and growth factors from mesenchymal cells and is now emerging as an important local orchestrator of neutrophil accumulation in several mammalian organs. Furthermore, there is growing evidence that targeting IL-17 signaling might prove useful in a variety of diseases including asthma, Crohn's disease, multiple sclerosis, psoriatric disease and rheumatoid arthritis. Here, we summarize the key aspects of the biology of IL-17 in mammals and scrutinize the potential pharmacological use of targeting IL-17 in humans. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Trends in Pharmacological Sciences
volume
30
issue
2
pages
95 - 103
publisher
Elsevier
external identifiers
  • wos:000263809500007
  • scopus:59549083038
ISSN
0165-6147
DOI
10.1016/j.tips.2008.11.004
language
English
LU publication?
yes
id
4cd3f2e9-ac63-4017-ab75-e9f3b6bf9fc1 (old id 1370843)
date added to LUP
2009-05-08 17:37:34
date last changed
2017-11-19 03:56:13
@article{4cd3f2e9-ac63-4017-ab75-e9f3b6bf9fc1,
  abstract     = {Interleukin (IL)-17 (now synonymous with IL-17A) is an archetype molecule for an entire family of IL-17 cytokines. Currently believed to be produced mainly by a specific subset of CD4 cells, named Th-17 cells, IL-17 is functionally located at the interface of innate and acquired immunity. Specifically, it induces the release of chemokines and growth factors from mesenchymal cells and is now emerging as an important local orchestrator of neutrophil accumulation in several mammalian organs. Furthermore, there is growing evidence that targeting IL-17 signaling might prove useful in a variety of diseases including asthma, Crohn's disease, multiple sclerosis, psoriatric disease and rheumatoid arthritis. Here, we summarize the key aspects of the biology of IL-17 in mammals and scrutinize the potential pharmacological use of targeting IL-17 in humans.},
  author       = {Ivanov, Stefan and Linden, Anders},
  issn         = {0165-6147},
  language     = {eng},
  number       = {2},
  pages        = {95--103},
  publisher    = {Elsevier},
  series       = {Trends in Pharmacological Sciences},
  title        = {Interleukin-17 as a drug target in human disease},
  url          = {http://dx.doi.org/10.1016/j.tips.2008.11.004},
  volume       = {30},
  year         = {2009},
}